Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check7 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0 on the page, signaling a new document revision. It appears to be a metadata/versioning update rather than a substantive change to study content.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates a new version of the page rendering, applied as a maintenance or QA update without altering study details or user interactions.SummaryDifference0.0%

- Check28 days agoChange DetectedA new line '2017 ( U.S. NIH Grant/Contract )' was added under Other Study ID Numbers, providing an additional funding identifier for the trial. This addition supplies extra context about funding but does not modify the study's primary data.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a new version of the page's documentation/template. This update records a small adjustment to the page's revision history.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.6.4 replaces the previous v3.6.3 on the page, indicating a small internal update. This change does not alter trial data, eligibility, or public content beyond the revision tag.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page's revision stamp changed from v3.6.0 to v3.6.3, indicating a newer version of the page content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.